State Key Laboratory of Food Science and Technology, The Engineering Research Center for Biomass Conversion, Nanchang University, Nanchang 330047, China.
Eco-Environmental Protection Research Institute, Shanghai Academy of Agricultural Sciences, Shanghai 201403, China.
Mar Drugs. 2021 Dec 12;19(12):703. doi: 10.3390/md19120703.
Microalgal cells serve as solar-powered factories that produce pharmaceuticals, recombinant proteins (vaccines and drugs), and valuable natural byproducts that possess medicinal properties. The main advantages of microalgae as cell factories can be summarized as follows: they are fueled by photosynthesis, are carbon dioxide-neutral, have rapid growth rates, are robust, have low-cost cultivation, are easily scalable, pose no risk of human pathogenic contamination, and their valuable natural byproducts can be further processed. Despite their potential, there are many technical hurdles that need to be overcome before the commercial production of microalgal pharmaceuticals, and extensive studies regarding their impact on human health must still be conducted and the results evaluated. Clearly, much work remains to be done before microalgae can be used in the large-scale commercial production of pharmaceuticals. This review focuses on recent advancements in microalgal biotechnology and its future perspectives.
微藻细胞是一种太阳能工厂,可以生产药物、重组蛋白(疫苗和药物)以及具有药用特性的有价值的天然副产品。微藻作为细胞工厂的主要优势可以概括如下:它们通过光合作用提供燃料,是二氧化碳中性的,具有快速的生长速度,稳健,培养成本低,易于规模化,不存在人类病原体污染的风险,其有价值的天然副产品可以进一步加工。尽管具有潜力,但在商业生产微藻药物之前,仍有许多技术障碍需要克服,并且必须对其对人类健康的影响进行广泛的研究并评估结果。显然,在微藻能够大规模用于商业生产药物之前,还有许多工作要做。本综述重点介绍了微藻生物技术的最新进展及其未来前景。